201 related articles for article (PubMed ID: 35444542)
1. Efficacy of Eribulin in Soft Tissue Sarcomas.
Phillips E; Jones RL; Huang P; Digklia A
Front Pharmacol; 2022; 13():869754. PubMed ID: 35444542
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas.
Noujaim J; Alam S; Thway K; Jones RL
Indian J Med Paediatr Oncol; 2016; 37(3):125-30. PubMed ID: 27688604
[TBL] [Abstract][Full Text] [Related]
3. Eribulin in advanced liposarcoma and leiomyosarcoma.
Setola E; Noujaim J; Benson C; Chawla S; Palmerini E; Jones RL
Expert Rev Anticancer Ther; 2017 Aug; 17(8):717-723. PubMed ID: 28621163
[TBL] [Abstract][Full Text] [Related]
4. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.
Schöffski P; Chawla S; Maki RG; Italiano A; Gelderblom H; Choy E; Grignani G; Camargo V; Bauer S; Rha SY; Blay JY; Hohenberger P; D'Adamo D; Guo M; Chmielowski B; Le Cesne A; Demetri GD; Patel SR
Lancet; 2016 Apr; 387(10028):1629-37. PubMed ID: 26874885
[TBL] [Abstract][Full Text] [Related]
5. Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: Translational results of the EORTC 62052 trial.
Wiemer EAC; Wozniak A; Burger H; Smid M; Floris G; Nzokirantevye A; Sciot R; Sleijfer S; Schöffski P
Eur J Cancer; 2017 Apr; 75():33-40. PubMed ID: 28214655
[TBL] [Abstract][Full Text] [Related]
6. The clinical outcome of eribulin treatment in Japanese patients with advanced soft tissue sarcoma: a Tokai Musculoskeletal Oncology Consortium study.
Nakamura T; Tsukushi S; Asanuma K; Katagiri H; Ikuta K; Nagano A; Kozawa E; Yamada S; Shido Y; Yamada K; Kawanami K; Ishimura D; Sudo A; Nishida Y
Clin Exp Metastasis; 2019 Aug; 36(4):343-350. PubMed ID: 31209624
[TBL] [Abstract][Full Text] [Related]
7. Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates.
Haddox CL; Nathenson MJ; Mazzola E; Lin JR; Baginska J; Nau A; Weirather JL; Choy E; Marino-Enriquez A; Morgan JA; Cote GM; Merriam P; Wagner AJ; Sorger PK; Santagata S; George S
Clin Cancer Res; 2024 Apr; 30(7):1281-1292. PubMed ID: 38236580
[TBL] [Abstract][Full Text] [Related]
8. Eribulin in Patients with Liposarcoma and Leiomyosarcoma: A Retrospective Single-Center Experience.
Steinbrecher O; Brodowicz T; Raderer M; Scharrer A; Fabsits J; Lamm W
Oncology; 2023; 101(2):89-95. PubMed ID: 36273457
[TBL] [Abstract][Full Text] [Related]
9. Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine.
Demetri GD; Schöffski P; Grignani G; Blay JY; Maki RG; Van Tine BA; Alcindor T; Jones RL; D'Adamo DR; Guo M; Chawla S
J Clin Oncol; 2017 Oct; 35(30):3433-3439. PubMed ID: 28854066
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Eribulin Plus Gemcitabine Combination in L-Sarcomas.
López-Álvarez M; González-Aguilera C; Moura DS; Sánchez-Bustos P; Mondaza-Hernández JL; Martín-Ruiz M; Renshaw M; Ramos R; Castilla C; Blanco-Alcaina E; Hindi N; Martín-Broto J
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614121
[TBL] [Abstract][Full Text] [Related]
11. Eribulin in the management of inoperable soft-tissue sarcoma: patient selection and survival.
Thomas C; Movva S
Onco Targets Ther; 2016; 9():5619-27. PubMed ID: 27672333
[TBL] [Abstract][Full Text] [Related]
12. Interim results of a real-world observational study of eribulin in soft tissue sarcoma including rare subtypes.
Kobayashi E; Naito Y; Asano N; Maejima A; Endo M; Takahashi S; Megumi Y; Kawai A
Jpn J Clin Oncol; 2019 Oct; 49(10):938-946. PubMed ID: 31365116
[TBL] [Abstract][Full Text] [Related]
13. Safety and effectiveness of eribulin in Japanese patients with soft tissue sarcoma including rare subtypes: a post-marketing observational study.
Kawai A; Narahara H; Takahashi S; Nakamura T; Kobayashi H; Megumi Y; Matsuoka T; Kobayashi E
BMC Cancer; 2022 May; 22(1):528. PubMed ID: 35546669
[TBL] [Abstract][Full Text] [Related]
14. The importance of treating by histological subtype in advanced soft tissue sarcoma.
Martín Broto J; Le Cesne A; Reichardt P
Future Oncol; 2017 Jan; 13(1s):23-31. PubMed ID: 27918201
[TBL] [Abstract][Full Text] [Related]
15. Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma.
Kawai A; Araki N; Naito Y; Ozaki T; Sugiura H; Yazawa Y; Morioka H; Matsumine A; Saito K; Asami S; Isu K
Jpn J Clin Oncol; 2017 Feb; 47(2):137-144. PubMed ID: 28173193
[TBL] [Abstract][Full Text] [Related]
16. Eribulin therapy for the treatment of patients with advanced soft tissue sarcoma.
Seetharam M; Kolla KR; Chawla SP
Future Oncol; 2018 Jul; 14(16):1531-1545. PubMed ID: 29411654
[TBL] [Abstract][Full Text] [Related]
17. Phase II Clinical Trial of Eribulin-Gemcitabine Combination Therapy in Previously Treated Patients With Advanced Liposarcoma or Leiomyosarcoma.
Kim CG; Sim NS; Kim JE; Yun KH; Lee YH; Kim SH; Baek W; Han YD; Kim SK; Kim JH; Koh YW; Jung I; Shin SJ; Rha SY; Ahn JH; Kim HS
Clin Cancer Res; 2022 Aug; 28(15):3225-3234. PubMed ID: 35583824
[TBL] [Abstract][Full Text] [Related]
18. A case of heavily pretreated metastatic cardiac angiosarcoma treated successfully using eribulin.
Inagaki C; Shimoi T; Okuma H; Kitano A; Shimomura A; Noguchi E; Kodaira M; Yunokawa M; Yonemori K; Shimizu C; Yoshida A; Fujiwara Y; Tamura K
Anticancer Drugs; 2018 Jan; 29(1):97-101. PubMed ID: 29176397
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy With Eribulin Following Potentially Curative Surgery in Patients With Localized Liposarcoma.
Steinbrecher O; Brodowicz T; Popov P; Lamm W
In Vivo; 2024; 38(1):385-389. PubMed ID: 38148100
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy of eribulin mesylate for the treatment of metastatic soft tissue sarcoma.
Emambux S; Italiano A
Expert Opin Pharmacother; 2017 Jun; 18(8):819-824. PubMed ID: 28468516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
